Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Common Stock Issued
Cash raised by issuing new shares.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued declines year over year
Q1 FY2026 common stock issued of $7K fell 100.0% year over year, behind the -43.2% change in trailing-twelve-month common stock issued. Sequentially, it fell 95.8% from the prior quarter. Over 3 fiscal years it compounded at -3.0% a year.
Context
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of -43.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 29.11M USD
- Year-over-year change
- +141.9%
- 4-year CAGR
- +17.5%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.11M | +141.9% |
| FY2024 | 2024-12-31 | 12.04M | +127.6% |
| FY2023 | 2023-12-31 | 5.29M | -83.4% |
| FY2022 | 2022-12-31 | 31.88M | +109.1% |
| FY2021 | 2021-12-31 | 15.25M | — |
Common Stock Issued vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 common stock issued of $13.61M is the 7th largest of the 11 companies compared; the peer median is $64.01M.
- Its year-over-year change of -43.2% is the 5th highest of 7, against a peer median of +306.6%.
- Over three fiscal years its annual growth of -3.0% compares with a peer median of +109.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $308M | +17301.2% | +114.8% | — | |
| LTM Mar 2026 | $216.27M | +376.4% | +103.6% | 436.2% | |
| LTM Mar 2026 | $212.95M | +1117.0% | +2184.5% | — | |
| LTM Mar 2026 | $143.13M | — | +19.7% | — | |
| LTM Mar 2026 | $107.36M | — | +216.5% | — | |
| LTM Mar 2026 | $20.66M | — | -57.8% | 9.5% | |
| LTM Mar 2026 | $13.61M | -43.2% | -3.0% | — | |
| LTM Mar 2026 | $7.94M | -97.9% | +119.6% | 36.7% | |
| LTM Jun 2026 | $4.36M | +236.8% | — | 2.6% | |
| LTM Mar 2026 | $140K | -82.4% | -50.8% | 0.1% | |
| LTM Mar 2026 | $38.73K | — | — | 7.7% | |
| Peer median (excluding NVCT) | $64.01M | +306.6% | +109.2% | 8.6% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.89M | 1.71M | 4.71M | 4.86M | 1.35M |
| Change in Working Capital | 1.49M | 3.82M | 1.74M | 1.9M | 4.4M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.85M | (139K) | (273K) | 3.78M |
| Other Working Capital | 1.49M | 1.97M | 1.88M | 2.17M | 625K |
| Other Non-Cash Items | 0 | 0 | (139K) | 0 | 4.68M |
| Operating Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.25M | 31.88M | 5.29M | 12.04M | 29.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.07M) | 9.8M | (382K) | 0 |
| Financing Cash Flow | 15.25M | 27.81M | 15.09M | 11.65M | 29.11M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.74M | 14.25M | (867K) | (593K) | 13.1M |
| Free Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.